Abstract Number: 2219 • ACR Convergence 2025
Transcriptomic and Immune Landscape of Recurrent Pregnancy Loss and Unexplained Infertility in Systemic Lupus Erythematosus
Background/Purpose: Recurrent pregnancy loss (RPL) and unexplained infertility (UIF) are significant reproductive health challenges in patients with systemic lupus erythematosus (SLE). SLE causes systemic inflammation…Abstract Number: 1982 • ACR Convergence 2025
Bridging the Gap in Underserved Care: A Quality Improvement Initiative to Increase Pneumococcal Vaccination Rates in Immunocompromised Rheumatology Patients
Background/Purpose: Patients with rheumatologic conditions who are on immunosuppressive therapy face an elevated risk of pneumococcal infections, particularly those in medically underserved populations. Per ACR…Abstract Number: 1859 • ACR Convergence 2025
Unraveling Disparities in Systemic Lupus Erythematosus-Related Mortality Among U.S. Adults (≥25 Years) with Malignancy: A Longitudinal Analysis of Gender, Race, and Geographic Inequities Using CDC WONDER (1999–2020)”
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that increases vulnerability to malignancy and premature mortality. Understanding long-term trends and disparities in SLE-related…Abstract Number: 1835 • ACR Convergence 2025
Serum Zonulin As A Biomarker Of Renal Involvement In Systemic Lupus Erythematosus: Shedding Light On The Gut-Kidney Axis
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease in which lupus nephritis (LN) remains a major cause of morbidity and mortality. Zonulin, a…Abstract Number: 1742 • ACR Convergence 2025
S100B in Childhood-onset Systemic Lupus Erythematosus: Associations with Disease Features, Interferon Levels, and Cognitive Functioning
Background/Purpose: Cognitive impairment is common in childhood-onset systemic lupus erythematosus (cSLE), particularly in domains like executive function and attention. However, attributing cognitive difficulties to brain…Abstract Number: 1686 • ACR Convergence 2025
The Prevalence of Depressive Symptoms and Persistent Depression among Older Adults with Systemic Lupus Erythematosus (SLE)
Background/Purpose: Depression is reported to be common in SLE, but little is known about depressive symptoms among older adults with SLE. While the burden of…Abstract Number: 1545 • ACR Convergence 2025
Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: Interim Analysis of a Phase 3 Randomized Placebo-controlled Study
Background/Purpose: Intravenous (IV) anifrolumab (300 mg, every 4 weeks [Q4W]) is an approved biologic add-on therapy for moderate to severe SLE;1 a subcutaneous (SC) formulation…Abstract Number: 1525 • ACR Convergence 2025
Rituximab super-responders: characteristics of patients with more than 3 years response to a single cycle of treatment
Background/Purpose: Emerging therapies such as CD19 CAR-T-cells have been reported to induce deeper B-cell depletion and thereby drug-free remission up to 18 months. With rituximab,…Abstract Number: 1503 • ACR Convergence 2025
Lupus Disease Activity Adversely Affects the Quality of Life but not Intimate Relationship and Sexual Function in Indian Female Lupus Patients
Background/Purpose: Systemic Lupus Erythematosus (SLE) disease activity can affect the normal functioning of the patients. This functioning in various domains can be assessed using quality…Abstract Number: 1486 • ACR Convergence 2025
Systemic Lupus Erythematosus and Statins in GLADEL 2.0: Are Cardiovascular Risk Prevention Guidelines Being Followed?
Background/Purpose: Patients (pts) with systemic lupus erythematosus (SLE) have a significantly increased risk of atherosclerotic cardiovascular disease (ASCVD). EULAR recommends a comprehensive assessment and management…Abstract Number: 1468 • ACR Convergence 2025
A HIPAA-Compliant LLM for Personalized Therapeutic Decision-Making in Lupus Nephritis
Background/Purpose: Lupus nephritis (LN) is the most significant driver of morbidity and mortality in patients with systemic lupus erythematosus (SLE). The ACR 2024 lupus nephritis…Abstract Number: 1279 • ACR Convergence 2025
Whole Blood Gene Expression Defined Subgroups of Treatment Naïve Children and Adolescents with Childhood-onset Systemic Lupus Erythematosus.
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a clinically and genetically heterogeneous disease. We aimed to define subgroups of new diagnosis patients based on treatment…Abstract Number: 1083 • ACR Convergence 2025
How Do Social Determinants of Health Differ Across Age and Disability Groups Among Adult Medicare Advantage Enrollees with Systemic Lupus Erythematosus?
Background/Purpose: Management of patients with SLE should consider social determinants of health (SDoH) and their impact on access, treatment, and patient outcomes; however, such a…Abstract Number: 0950 • ACR Convergence 2025
Ep300-Catalyzed Rad50 Lactylation Compromises Genomic Stability and Drives CD4+T cells Cell Senescence in SLE
Background/Purpose: Senescent CD4+ T cells are increasingly implicated in systemic lupus erythematosus (SLE) pathogenesis. While metabolic reprogramming in lupus T cells enhances glycolysis and lactate…Abstract Number: 0913 • ACR Convergence 2025
Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates In Vitro and In Vivo Activity Comparable or Superior to Approved or Clinically Active Agents in Human Cellular Assays and Lupus Efficacy Models
Background/Purpose: IRF5 is a transcription factor and regulator of immune responses activated downstream of pattern recognition receptors, in particular endosomal toll-like receptors (TLR), TLR7, TLR8…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 181
- Next Page »